Armesocarb

Armesocarb
Clinical data
Other names	(R)-Mesocarb; L-Mesocarb; MLR-1019; MLR1019
Drug class	Atypical dopamine reuptake inhibitor
Identifiers
	IUPAC name N-phenyl-N'-[3-[(2R)-1-phenylpropan-2-yl]oxadiazol-3-ium-5-yl]carbamimidate;
CAS Number	34262-84-5;
PubChem CID	7130196;
ChemSpider	5473777;
UNII	UMT8MP2NDU;
Chemical and physical data
Formula	C18H18N4O2
Molar mass	322.368 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H](CC1=CC=CC=C1)[N+]2=NOC(=C2)N=C(NC3=CC=CC=C3)[O-];
	InChI InChI=1S/C18H18N4O2/c1-14(12-15-8-4-2-5-9-15)22-13-17(24-21-22)20-18(23)19-16-10-6-3-7-11-16/h2-11,13-14H,12H2,1H3,(H-,19,20,21,23)/t14-/m1/s1; Key:OWFUPROYPKGHMH-CQSZACIVSA-N;

Armesocarb (developmental code name MLR-1019), also known as (R)-mesocarb or L-mesocarb, is a selective atypical dopamine reuptake inhibitor (DRI). It is currently under development for the treatment of Parkinson's disease and sleep disorders.^[1]^[2]

It is the active (R)-enantiomer of the formerly clinically used stimulant-like drug mesocarb (MLR-1017; brand name Sydnocarb).^[1]^[2]^[3]

^ ^a ^b "Melior Pharmaceuticals". AdisInsight. 28 April 2023. Retrieved 26 September 2024.
^ ^a ^b Macolino-Kane CM, Ciallella JR, Lipinski CA, Reaume AG (14 July 2017). "Phenotypic Screening". Drug Repositioning. Frontiers in Neurotherapeutics. Boca Raton: CRC Press. pp. 121–145. doi:10.4324/9781315373669-7. ISBN 978-1-315-37366-9.
^ Cite error: The named reference Al'tschuler2005 was invoked but never defined (see the help page).